Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

VVOS

VVOS News

Newswire

13:19

Ascendiant Capital Maintains Vivos Therapeutics Buy Recommendation

07:01

Ascendiant Capital Maintains Buy Rating, PT Down to $5.5 for Vivos.

22:31

Vivos Therapeutics Q3 Revenue Surges 78% Amid Strategic Shift

20:35

Vivos Therapeutics Q3 2025 Earnings Call Recap: Key Takeaways and Plans for 2025 and Beyond

16:21

Vivos Therapeutics Reports 78% Sequential Revenue Growth in Q3 2025, Shows Impact of Sleep Center of Nevada Acquisition

View More

About VVOS

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More